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ORIGINAL RESEARCH–OTOLOGY AND NEUROTOLOGY
Induced endolymphatic ﬂow from the
endolymphatic sac to the cochlea in Ménière’s
disease
Marco Mandalà, MD, Liliana Colletti, PhD, Marco Carner, MD,
Roberto Cerini, MD, Marco Barillari, MD, Roberto Pozzi Mucelli, MD, and
Vittorio Colletti, MD, Verona, Italy
No sponsorships or competing interests have been disclosed for
this article.
ABSTRACT
OBJECTIVE: The aim of the present study was to verify
whether drugs injected into the endolymphatic sac (ES) can reach
the cochlea and possibly treat inner ear disorders.
STUDY DESIGN: Prospective cohort study.
SETTING: Tertiary referral center, Otolaryngology Department,
University of Verona.
SUBJECTS AND METHODS: Patients with Ménière’s dis-
ease (MD) who were candidates for ES decompression were se-
lected. Nineteen subjects received dexamethasone (DEX) via in-
jection into the ES. To objectively deﬁne whether substances
administered into the ES could reach the cochlea, we added gad-
olinium (GD) in three patients. All subjects had intraoperative
electrocorticogram recordings and an audiologic follow-up. The
three subjects who underwent injection of the DEX-GD solution
were followed-up with magnetic resonance imaging. The audio-
logical data are presented during a follow-up period of 12 months.
RESULTS: Intraoperative electrocochleography recordings re-
vealed no changes in two patients and summating potentials and
compound action potential latency and wave-form modiﬁcations in
all the other subjects. GD distribution was observed from 48 hours
to one week after ES injection into the cochlea of the three subjects
injected with DEX-GD. GD-related enhancement of inner ear
structures lasted more than two weeks in all subjects. Pure tone
average results showed hearing improvement of at least 20 dB HL
in 42 percent of patients (8 of 19) at the 12-month follow-up.
Statistically signiﬁcant differences emerged between the mean
pure tone average of the ES procedure subjects at one and 12
months after surgery (P  0.0096).
CONCLUSION: This novel approach might reveal new pros-
pects for treating viral, metabolic, autoimmune, and genetic dis-
orders of the cochlea.
© 2010 American Academy of Otolaryngology–Head and Neck
Surgery Foundation. All rights reserved.
Emerging therapies such as stem cells, gene therapy, andneurotrophic factors may open up new prospects for the
treatment of inner ear disorders. In particular, patients with
sudden hearing loss, immunomediated disorders, and
Ménière’s disease (MD) could beneﬁt from these new ther-
apies. Most of these diseases constitute a major challenge
for ENT doctors because there is no deﬁnitive and effec-
tive treatment.1,2 Today for MD, only vertigo spells can
be treated effectively with ablative procedures, whereas
hearing loss and tinnitus remain unsolved problems.
The bloodlabyrinthine barrier acts similarly to the
bloodbrain barrier by limiting the diffusion of systemic
drugs to the inner ear.3 At the present time, two local
procedures4 are being studied to administer drugs into the
inner ear compartments in humans: 1) intratympanic (IT)
delivery, which involves depositing the therapeutic agent in
the middle ear; and 2) intracochlear delivery, which depends
on injection either through the round window membrane or
via a cochleostomy. The perilymphatic compartment is the
target of these two methodologies, but only the IT route has
been widely adopted to deliver steroids to the human co-
chlea. The results of such therapy are often unpredictable,1
and part of this substantial variability of results, ranging
from complete recovery to no improvement, may be attrib-
utable to inadequate distribution into the endolymphatic
compartments (ECs). To the best of our knowledge, none of
the previously described methodologies have yielded either
radiologic or electrophysiologic evidence of distribution
into the human ECs. Promising results with stem cells5,6 and
mostly gene therapy administered via the scala media in
animal models7-9 could be the basis for developing new
effective strategies for treating inner ear disorders.
Among hearing preservation procedures in MD, en-
dolymphatic sac (ES) surgery has been considered a safe
procedure, and in our opinion the ES might represent an
appropriate entrance route to the endolymphatic space of the
scala media (ESp-SM). Animal models have shown that ES
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injections of viral vectors can successfully reach the ESp-
SM,10 and cochlear hair cell regeneration has been achieved
after endolymphatic injections of Math1 gene via the ESp-
SM.7,8
In humans, the therapeutic potential of steroid instillation
into the ES in MD has been explored by Kitahara et al,11
who discovered good outcomes in terms of controlling
spells of vertigo and hearing function. However, these au-
thors combined the procedure with drainage of the sac,
thereby biasing the individual effect of each procedure.
The aim of the present study was to objectively verify
with imaging or intraoperative electrophysiology whether
substances injected into the ES can indeed reach the co-
chlea. Nineteen patients with MD undergoing ES decom-
pression participated at the study: three patients received an
injection of dexamethasone (DEX) in addition to gadolin-
ium (GD) into the ES, and 16 received DEX alone. To
monitor the possible hydrodynamic effects of modifying
endolymphatic pressure and volume12-14 with the injection
of ﬂuid (DEX plus GD or GD alone) into the ES, all patients
had intraoperative electrocochleography (ECoG) record-
ings. An audiologic and neuro-otologic follow-up was con-
ducted to investigate the safety and effectiveness of the ES
procedure. In addition, the three patients receiving DEX
plus GD underwent serial magnetic resonance imaging
(MRI) studies. Here, the ﬁndings, potential, and limitations
of this novel procedure are discussed.
Materials and Methods
The present study is a prospective cohort study on patient-
based clinical population recruited during the period from
January 2008 to January 2009. The study was conducted at
the Department of Otolaryngology (tertiary referral center)
of the University of Verona (Verona, Italy). All participants
were affected by deﬁnite MD, according to the criteria of
the American Academy of Otolaryngology-Head and Neck
Surgery;15 they had also received medical therapy (diuret-
ics, betahistine, low-salt diet) for at least six months. All
participants performed a complete audiologic evaluation
with pure tone audiometry (PTA), speech audiometry, im-
pedance audiometry, auditory brainstem-evoked potentials,
ECoG, and electrical promontory stimulation with IT elec-
trodes and the Tinnitus Handicap Inventory (THI). They
also underwent a neuro-otologic evaluation that included an
eye-movement bedside examination, caloric test, and ves-
tibular-evoked myogenic potentials (VEMPs).
Nineteen patients met the inclusion criteria and were
submitted to ES decompression. Sixteen patients underwent
ES decompression with injection of DEX alone. Three pa-
tients accepted the procedure with local administration of a
DEX-GD solution. Patients underwent classic ES decom-
pression and received 27-gauge spinal needle injections into
the ES with 0.2 mL of DEX alone (dexamethasone sodium
phosphate 4 mg/1 mL; Mayne Generics) or DEX plus
20 percent gadobutrol (10-[(1SR,2RS)-2,3-dihydroxy-1-
hydroxy-methylpropyl]-1,4,7,10-tetraazacyclo-dodecane-
1,4,7-triacetic acid, gadolinium-complex; Gadovist, Scher-
ing SpA).
The 27-gauge Whitacre spinal needle was modiﬁed to
make it suitable for reaching the ES correctly (Fig 1). ES
injections into the ES were performed with 0.2 mL of
solution at a ﬂow rate of approximately 0.1 mL/s. The
injections were done by hand with a 1-mL insulin syringe,
and its rate was only approximately measured. Complete
surgical exposure of the ES up to the ED was obtained (Fig
2) to inject the solution into the lumen of the ES and
visualize its dilatation as a result of the injection.
Intraoperative ECoG potentials (summating potentials
[SPs] and compound action potentials [CAPs]) were re-
corded from electrodes placed on the round window with a
reference on the ipsilateral tragus during pressure and volu-
metric changes of inner ear structures caused by the admin-
istration of the solution. A 10-channel evoked potential
system (Medelec Synergy N-EP, VIASYS Healthcare, San
Diego, CA) was used with a ﬁlter setting of 3 Hz to 3 KHz
and a 2.5-mV ampliﬁer. The recorded potentials were stored
and analyzed ofﬂine.
Postoperative 1.5-T MRI follow-up evaluations were
performed for the ﬁrst week and weekly for the subsequent
three weeks in patients who underwent ES administration of
the DEX-GD solution. Inner ear structures were studied
with three-dimensional Fourier transformation-constructive
interference in the steady state (FT-CISS), spin echo T1-
weighted sequences.
The 1.5-T MRI scans were performed by the use of a
1.5-T Magnetom Symphony Maestro Class device (Syngo
MR 2002B model; Siemens, Erlangen, Germany) and a CP
Head Array Coil (Siemens). A coronal T2-weighted se-
quence (TR 4850, TE 108, thickness 4 mm) was acquired as
a scout view. The following scan was a gradient echo
three-dimensional T1-weighted image (144 slices, ﬂip angle
12°, thickness 1 mm, matrix 256  256 interpolation) to
have a general view of the brain. Inner ear structures were
studied in the axial plane with two sequences: three-
dimensional 3D FT-CISS (28 slices, TR 13.88, TE 6.94,
thickness 0.70 mm, ﬂip angle 70°, matrix 320  320
interpolation), including maximum intensity projection
volumetric reconstructions, and spin echo T1-weighted
Figure 1 Needle preparation. The 27-gauge Whitacre (circle)
spinal needle is modiﬁed to make it suitable for reaching the ES:
two curvatures are produced (arrows).
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images (12 slices, TR 578, TE 17, thickness 2.5 mm, fat
suppression, matrix 256  256). Three-dimensional FT-
CISS images were obtained to furnish a correct anatom-
ical view of the cerebellopontine angle and of the laby-
rinthine ﬂuid spaces. An axial spin echo sequence was
performed to highlight the presence of the paramagnetic
contrast agent and to identify its position.
Clinical, audiologic, and neuro-otologic follow-up eval-
uations were performed at one, three, six, and 12 months.
Signiﬁcant hearing improvement or deterioration was con-
sidered when the PTA presented changes of at least 20 dB
HL. Differences between groups were tested by the use of t
test and nonparametric test (Mann–Whitney U test/2 test;
two-tailed) as appropriate.
All patients were informed as to the experimental pro-
cedures and signed a consent form. The procedures were
approved by the Ethics Committee of the University of
Verona School of Medicine.
Results
All patients but one completed the 12-month follow-up.
This patient complained of incapacitating vertigo spells
during follow-up (2 months after surgery) and subsequently
underwent vestibular neurectomy to control the symptoms
effectively. Intraoperative ECoG recordings were per-
formed in all patients. In two patients, no changes could be
observed with intraoperative ECoG after ES injection. One
is the patient that, after obtaining no beneﬁt from endolym-
phatic surgery, underwent vestibular neurectomy; the other
patient had severe cochlear otosclerosis and had no changes
in tinnitus and hearing threshold after sac surgery. In all the
other subjects, changes in the wave-form or an increase in
latency (mean, 0.24 ms; range, 0.16-0.39 ms) two to 10
minutes after the injection could be observed. Wave-form
changes consisted mainly in modiﬁcations of SPs (9 sub-
jects) and/or CAP amplitude variations (12 patients). Only
one patient experienced an isolated increase in latency,
whereas all other subjects showed associated latency and
wave-form changes (Fig 3). All these changes reverted to
normal within 20 to 60 minutes after the injection.
Distribution of GD was observed after a few hours in the
ES area of the three subjects. A few hours after injection, it
was not always easy to differentiate GD enhancement from
blood in the area of the ES (Fig 4). All subjects showed
initial distribution of GD from the ES to the vestibule and
semicircular canals and subsequently to the basal, middle,
Figure 2 Surgical view of the exposed ES (right ear). (A)
Mastoidectomy with exposure of the posterior semicircular canal
(short arrowhead), sigmoid sinus gently depressed with the sig-
moid sinus retractor (long arrowhead), retrofacial area (circle), ES
(long arrow), and ED (asterisk). The spinal needle (short arrow) is
inserted into the ES. (B) The injection produced distinct dilatation
of the ES (arrow).
Figure 3 Intraoperative ECoG recordings during ES DEX ad-
ministration. Increased latency and change in CAPs morphology
with appearance of SPs (circle) are evident ﬁve to 10 minutes after
injection.
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and apical turns of the cochlea (Fig 5). Enhancement of the
ES area was observed within four hours of the procedure.
After approximately 24 hours, distribution of the GD was
observed in the vestibule and semicircular canals in all
subjects.
After 48 hours, GD diffusion was observed in the co-
chlear basal turn of two patients. In these two patients, all
cochlear turns appeared clearly enhanced at 96 hours,
whereas the other patient showed only faint enhancement of
the basal turn. At the one-week examination, high gadolin-
ium signal up to the apical turn was observed in all subjects.
Reliable enhancement of the ECs of the patients was
observed two weeks or more after injection (mean, 16.3
days; range, 14-21 days). No GD-related contrast enhance-
ment of cerebrospinal ﬂuid was observed during the MRI
follow-up, and no side effects were observed in any of the
participants.
Table 1 summarizes the mean results of the PTA, THI,
caloric test, and VEMPs at baseline and at one, three, six,
and 12 months’ follow-up. PTA results showed signiﬁcant
hearing improvement in 42 percent of patients (8 of 19) at
the 12-month follow-up examination. The mean PTA at
baseline and at the 12-month test was 48.04 12.54 dB HL
and 33.42  18.74 dB HL, respectively. Statistically sig-
niﬁcant differences emerged between the baseline mean
PTA and the 12-month control (P  0.0096). Four patients
Figure 4 MRI T1-weighted spin echo, axial view images of ES GD-DEX administration (2 subjects: left ears). (A) Four hours after ES
administration: high GD signal in the ES (arrow). (B) Six hours after ES administration: high GD signal in the surgical ﬁeld and ES area
(arrow).
Figure 5 MRI T1-weighted spin echo, axial view images of ES GD-DEX administration (left ear). (A) At 24 hours after ES
administration: high GD signal in the vestibule (short arrow). (B) At 48 hours after ES administration: GD-related enhancement in the
vestibule (short arrow) and cochlear basal turn (long arrow). (C) At 96 hours after ES administration: high GD signal in the vestibule (short
arrow), posterior semicircular canal (arrowhead), and all the cochlear turns (3 arrows).
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showed hearing deterioration at the 12-month follow-up. At
the one-month follow-up, most of the patients experienced
a signiﬁcant (P 0.0285) subjective reduction in tinnitus as
documented by the THI total score (Table 1). This trend was
conﬁrmed as stable in subsequent examinations. No statis-
tically signiﬁcant differences emerged in the caloric test or
in VEMPs at follow-up.
Discussion
Currently, the most widely adopted therapeutic procedure
for treating acquired inner ear disorders is the IT adminis-
tration of drugs. Steroid injections through the tympanic
membrane are routinely performed for treating sudden hear-
ing loss, immunomediated disorders, and MD. The radio-
logical demonstration that perilymphatic and not endolym-
phatic diffusion of intratympanic GD may be observed in
MD subjects16,17 could account for the variability of the
results of IT steroid therapy1,18 and the absence of evidence-
based conclusions that the treatment is effective. Other
surgical approaches, such as direct round window adminis-
tration19 or the cochleostomy route, as used for cochlear
implants,4 may cause trauma, infection, and, in any case,
may not offer the possibility of reaching the ESp-SM.20
To the best of our knowledge, the ES approach described
here may be a possible route capable of providing distribu-
tion of substances into the human cochlea. The present
study yielded both radiologic and electrophysiologic evi-
dence that substances injected into the human ES can reach
the cochlea, presumably the ESp-SM. At the 12-month
audiologic and neuro-otologic follow-up, the ES injection
procedure appeared safe for residual hearing and vestibular
function.
The ES injection procedure with DEX-GD solution
showed gradual GD diffusion from the ES and duct up to
the apical turn of the cochlea in all subjects, which lasted
more than two weeks in the inner ear. There was no evi-
dence of cerebrospinal ﬂuid enhancement at the MRI fol-
low-up examination. This ﬁnding indicates that the injec-
tion was performed between the two layers of the ES into
the endolymphatic space without damaging the deeper
layer. Furthermore, the procedure of injecting the
DEX-GD solution may be considered safe for residual
hearing function because no patients showed any signif-
icant PTA deterioration.
Signiﬁcant changes in SPs and CAPs were observed with
dilatory injections in all but two patients who presented no
changes in SPs and/or CAPs. One of these subjects had
severe cochlear otosclerosis that could have prevented pres-
sure and/or volume increases in the ESp-SM after injection.
In all other patients, ES injection-related pressure and/or
volume changes may have been rapidly (within 60-100
seconds) transmitted to the ESp-SM and returned to normal
after 20 to 60 minutes. However, temporary modiﬁcations
in the SP and CAPs could be also ascribed to temporary
changes in the ionic composition of the endolymph or to
minor and reversible traumatic effects. These ﬁndings
clearly suggest that the ES procedure produces signiﬁcant
modiﬁcations of the ESp-SM as experimentally demon-
strated by Salt et al.12
According to the ECoG ﬁndings, it may be assumed that
the substances administered into the ES may be distributed
through the ECs to ESp-SM, conﬁrming the results of pre-
vious studies in the animal model.8 The slow distribution
and lengthy permanence of GD along the inner ear may be
further proof of the distribution of GD into the ESp-SM
because of the extremely low ﬂow rate of endolymph in
normal conditions and its relative isolation.
The audiologic examination showed a slightly greater
percentage of patients with PTA threshold improvement as
Table 1
Audiologic and neuro-otologic results of the population
ES injection patients
Audiologic and neuro-otologic follow-up
Baseline 1 month 3 months 6 months 12 months
PTA, dB HL, mean  SD 48.04  12.54 51.02  11.21 42.19  19.36 36.68  22.27 33.42  18.74
Statistical analysis between
follow-up times,
baseline versus: P  0.4451 P  0.2777 P  0.0628 P  0.0096*
THI, total score,
mean  SD 35.2  19.3 21.6  16.8 26.9  17.4 22.7  12.3 22.3  14.1
Statistical analysis between
follow-up times,
baseline versus: P  0.0285* P  0.1660 P  0.0227* P  0.0253*
Caloric weakness (caloric
paresis/paralysis), % 84 94 89 89 89
VEMPs, absence, % 63 63 68 74 74
ES, endolymphatic sac; PTA, pure tone average; THI, Tinnitus Handicap Inventory; VEMPs, vestibular-evoked myogenic potentials.
*Statistically signiﬁcant.
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compared with the ﬁndings of Kitahara et al11 (42% vs
36.5%). Differences in the criteria adopted to deﬁne hearing
improvement (10 dB HL vs 20 dB HL in the present study)
and in follow-up time (7 years vs 12 months) emerged
between these two studies. The results of ES injection of the
steroid showed better outcomes, albeit only with a short
follow-up period. These promising data seem to show an
additional beneﬁcial effect of steroid administration into the
ECs and dilation of the ES as compared with ES decom-
pression alone.
The ES injection procedure controlled spells of vertigo in
95 percent of patients. No cases of vestibular ablation re-
lated to the procedure were observed. Furthermore, no sta-
tistically signiﬁcant differences emerged in the caloric test
or in VEMPs at follow-up. These data are in agreement with
the recent ﬁnding that acute endolymphatic hydrops has no
effect on the vestibular system in the animal model.21
The main limitations of our study are the short follow-up,
the absence of a randomized control group, and the resolu-
tion of the 1.5-T MRI that showed the cochlea as a single
enhanced canal. The use of 3.0-T MRI would have made it
possible to differentiate between perilymphatic and en-
dolymphatic spaces. In addition, the observation that GD
distributes from the ES to the ESp-SM does not necessarily
predict the pharmacokinetics of other substances into the
inner ear compartments.
Among the different drug-delivery methods for reaching
the inner ear, the deposition of substances into the ES might
afford an excellent drug access point that could be extended
to gene5,22 and stem cell6 therapy. In particular, this new
approach could be used to deliver substances to the inner ear
with different strategies. “Single-shot therapy” via the ES
route would be suitable for the treatment of sensorineural
hearing loss and/or vestibular deﬁcits with stem cells5,6 and
gene therapy.7-9 The end point of single shot therapy should
be the regeneration of cochlear and/or vestibular hair cells.
The ES approach has the advantage of directly reaching the
endolymphatic space, which is an ideal anatomical compart-
ment for such therapies because of its peculiarities: small
size and relative isolation.
Patients with sudden hearing loss, immunomediated in-
ner ear disorders such as Cogan syndrome, and prevention
of iatrogenic ototoxicity (radiotherapy, aminoglycosides, or
cisplatin) could beneﬁt from “prolonged therapy” with ste-
roids and neurotrophic factors. Despite the protracted dis-
tribution of GD obtained in the cochlea, this type of ES
administration must rely on the development of slow-re-
lease biodegradable polymers and nanoparticle delivery.4
“Continuous therapy” may be possible when fully implant-
able devices (microcatheters or pumps with rechargeable
reservoirs) have been developed for humans.
In conclusion, the ES injection procedure offers a great
opportunity of reaching the cochlea and presumably the
endolymphatic space safely. This novel route might consti-
tute an advance in therapy for inner ear disorders. Reaching
the ECs may be essential to achieve results worthy of note
with local therapy. Recently developed therapies and con-
ventional local treatments might beneﬁt greatly from this
procedure. Larger randomized controlled studies are neces-
sary to verify the efﬁcacy of each treatment proposed using
this novel route.
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